AB Sciex Q-Trap 5500 LC/MS/MS

AB Sciex Q-Trap 5500 LC/MS/MS

• 批准号: 7793254
• 负责人: Jennifer E Van Eyk
• 金额: $ 49.87万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-08 至 2011-04-07
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7793254
• 关键词: Address; Antibodies; Biological Assay; Biological Markers; Biology; Blood Vessels; Cardiology; Clinical; Clinical Medicine; Cystic Fibrosis; Data Analyses; Data Quality; Development; Diabetes Mellitus; Ensure; Enzyme-Linked Immunosorbent Assay; Equipment; Funding; HIV; Human; Laboratories; Liquid substance; Malignant Neoplasms; Proteins; Proteome; Request for Proposals; Research Personnel; Sampling; Sickle Cell Anemia; Stroke; System; Time; Work; assay development; cohort; experience; instrument; mass spectrometer; multiple reaction monitoring; nano; numb protein; public health relevance; translational study

DESCRIPTION (provided by applicant): This proposal requests funds for an Applied Biosystems SCIEX QTRAP 5500 mass spectrometer with an Ultra 2D nano liquid chromatographic (LC) system from Eksigent, This system has been chosen specifically for the clinical/translational studies in which absolute quantification of a single or many proteins is obtained using an approach known as multiple reaction monitoring (MRM). MRM assays produce the same quality data as a ELISA but without the need for antibodies. Thus, MRM condenses the time and expense of quantitative assay development for one or more protein in clinical sample sets. Furthermore, multiplex MRM assays eliminate the need for antibody arrays, which are technically challenging and often limited. We will be using the QTRAP 5500 LC/MS/MS specifically for MRM assays in the context of large clinical cohorts where the unique aspects of this equipment are essential. Examples include situations where (i) a large number of proteins (40+), and their modified forms are assayed simultaneously, (ii) maximal sensitivity is needed for broad proteome coverage (1e7+), (iii) large sample sets (500+) must be examined and (iv) only very small quantities of irreplaceable samples are available. A group of very experienced investigators with targeted studies to address key clinical questions will use the QTRAP 5500. Seven teams constitute the major users and include researchers and MS experts from the Johns Hopkins CTSA/ITCR Biomarker Development Center directed by Jennifer Van Eyk, and the laboratories of Anne Murphy, Allen Everett and James Casella, Josef Coresh, M. Christine Zink and David Graham, Harry (Hal) Dietz as well as Gerald Hart. The researchers will work collaboratively to maximize the instrument use and to ensure high quality and effective data analysis. The projects address clinical questions in cardiology, vascular biology, stroke, diabetes, sickle cell anemia, cystic fibrosis, cancer, and HIV. Each project is poised to impact clinical medicine. PUBLIC HEALTH RELEVANCE: This proposal requests funds for a mass spectrometer capable of quantifying specific proteins in clinical samples. The unique aspects of this particular instrument is it's (i) ability to simultaneously analyze a large number of proteins and their modified forms (40+), (ii) increased sensitivity which maximizes proteome coverage (1e7+), (iii) capability to analyze large sample numbers (500+) with (iv) very small quantities of human clinical samples. The projects address important and pressing clinical questions in cardiology, vascular biology, stroke, diabetes, sickle cell anemia, cystic fibrosis, cancer, and HIV. Each project is poised to impact clinical medicine.

描述（由申请人提供）：本提案请求资金购买带有 Eksigent 的 Ultra 2D 纳米液相色谱 (LC) 系统的 Applied Biosystems SCIEX QTRAP 5500 质谱仪。该系统专门用于临床/转化研究，其中使用称为多反应监测 (MRM) 的方法获得单个或多个蛋白质的绝对定量。 MRM 检测可产生与 ELISA 相同的质量数据，但不需要抗体。因此，MRM 压缩了临床样品集中一种或多种蛋白质定量测定开发的时间和费用。此外，多重 MRM 测定无需抗体阵列，而抗体阵列在技术上具有挑战性且通常受到限制。我们将使用 QTRAP 5500 LC/MS/MS 专门用于大型临床队列中的 MRM 测定，其中该设备的独特之处至关重要。例子包括以下情况：(i) 同时检测大量蛋白质 (40+) 及其修饰形式，(ii) 广泛的蛋白质组覆盖 (1e7+) 需要最大灵敏度，(iii) 必须检查大样本集 (500+)，以及 (iv) 只有非常少量的不可替代样本可用。一组经验丰富的研究人员将使用 QTRAP 5500 进行有针对性的研究，以解决关键的临床问题。七个团队构成了主要用户，包括来自 Jennifer Van Eyk 指导的约翰霍普金斯大学 CTSA/ITCR 生物标志物开发中心的研究人员和 MS 专家，以及 Anne Murphy、Allen Everett 和 James Casella、Josef Coresh、M. Christine Zink 和 David Graham、Harry (Hal) Dietz 的实验室 还有杰拉尔德·哈特。研究人员将共同努力，最大限度地利用仪器并确保高质量和有效的数据分析。这些项目解决心脏病学、血管生物学、中风、糖尿病、镰状细胞性贫血、囊性纤维化、癌症和艾滋病毒等方面的临床问题。每个项目都准备影响临床医学。 公共健康相关性：该提案要求为能够量化临床样本中特定蛋白质的质谱仪提供资金。这种特殊仪器的独特之处在于 (i) 能够同时分析大量蛋白质及其修饰形式 (40+)，(ii) 提高灵敏度，最大限度地提高蛋白质组覆盖率 (1e7+)，(iii) 能够使用 (iv) 极少量的人类临床样本分析大量样本 (500+)。这些项目解决了心脏病学、血管生物学、中风、糖尿病、镰状细胞性贫血、囊性纤维化、癌症和艾滋病毒等方面重要而紧迫的临床问题。每个项目都准备影响临床医学。